Am J Perinatol 2024; 41(08): 1027-1032
DOI: 10.1055/a-1787-3838
Original Article

Cord Blood Cell-Free DNA Concentration: A Novel Marker for Neonatal Wellbeing

1   Department of Obstetrics and Gynecology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
2   Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
,
Offer Erez
3   Department of Obstetrics and Gynecology, HaEmek Medical Center, Afula, Israel
4   Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan
,
Dan Tirosh
1   Department of Obstetrics and Gynecology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
,
Yael Miller Gelkop
5   Department of Life Sciences, Faculty of Natural Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
,
Neta Benshalom-Tirosh
6   Department of Clinical Biochemistry and Pharmacology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
,
Maor Ben-Tabo
7   Department of Obstetrics and Gynecology, Assuta Medical Center, Ashdod, Israel
,
Amos Douvdevani
7   Department of Obstetrics and Gynecology, Assuta Medical Center, Ashdod, Israel
› Author Affiliations
Funding None.

Abstract

Objective Cord gas values and Apgar scores, currently used as markers for newborn wellbeing and postpartum complications, provide rough estimates, and their use remains elusive. Circulating cell-free DNA (cfDNA) may better represent newborn status at birth and the effect of parturition on the fetus. This pilot study investigates the association between cord blood (CB) cfDNA and neonatal outcomes.

Study Design In a prospective cohort study, cfDNA concentration was measured in immediately following delivery collected CB sera of newborns using our rapid fluorescent assay.

Results During the study period, blood samples from umbilical cords of 100 newborns were collected. Vaginal delivery was associated with a higher median CB cfDNA than cesarean delivery (277 [95% confidence interval [CI] 199–377] vs. 100 [95% CI 43–265] ng/mL, p < 0.01). cfDNA levels were significantly associated with gestational age at delivery (rho = 0.308, p = 0.002) and CB base deficit (BD, r = 0.252, p = 0.017). According to maternal and fetal complications, CB cfDNA was elevated in fetuses with category II of heart rate tracing (p < 0.05), with maternal positive vaginal culture (p < 0.01), and with premature rupture of membranes (PROM, p < 0.001). Logistic regression models of CB cfDNA fourth quartiles demostrate a double odds ratio for elevated BD (>3mmol/L) and for worse heart rate tracing category.

Conclusion Serum CB cfDNA concentration reflects the newborn's status and hazards with an excellent association with CB BD, fetal heart rate category, and maternal risk factors for infection (positive vaginal culture and PROM). This preliminary observation suggests that cfDNA can serve as a point of care biomarker for newborn status at the time of delivery.

Key Points

  • CB cfDNA levels correlated with newborn's BD.

  • CB cfDNA levels reflect parturition stress and inflammation.

  • cfDNA serve as a diagnostic and prediction tool for the identification of newborns at risk for morbidity.

Ethical Approval

This study protocol was approved by the institutional review board (SUMC IRB committee).


Authors' Contributions

M.I. contributed to protocol/project development, analysis interpretation, data management, and manuscript writing. O.E. contributed to protocol/project development, analysis interpretation, data management, and manuscript editing. D.T. contributed to analysis interpretation and manuscript editing. Y.M.G. contributed to data analysis. N.B.T. contributed to analysis interpretation and manuscript editing. M.B.T. contributed to data analysis. A.D. contributed to protocol/project development, analysis interpretation, data management, and manuscript editing.




Publication History

Received: 05 June 2021

Accepted: 17 February 2022

Accepted Manuscript online:
03 March 2022

Article published online:
06 June 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Modanlou H, Yeh S-Y, Hon EH, Forsythe A. Fetal and neonatal biochemistry and Apgar scores. Am J Obstet Gynecol 1973; 117 (07) 942-951
  • 2 Yeh P, Emary K, Impey L. The relationship between umbilical cord arterial pH and serious adverse neonatal outcome: analysis of 51,519 consecutive validated samples. BJOG 2012; 119 (07) 824-831
  • 3 Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anest Anal 1953; 32 (04) 260-267
  • 4 Weiss SL, Fitzgerald JC, Balamuth F. et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014; 42 (11) 2409-2417
  • 5 Low JA, Lindsay BG, Derrick EJ. Threshold of metabolic acidosis associated with newborn complications. Am J Obstet Gynecol 1997; 177 (06) 1391-1394
  • 6 Wan JCM, Massie C, Garcia-Corbacho J. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17 (04) 223-238
  • 7 Saukkonen K, Lakkisto P, Pettilä V. et al; Finnsepsis Study Group. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem 2008; 54 (06) 1000-1007
  • 8 Netz U, Perry Z, Mizrahi S. et al. Cell-free deoxyribonucleic acid as a prognostic marker of bowel ischemia in patients with small bowel obstruction. Surgery 2017; 162 (05) 1063-1070
  • 9 Zhong XY, von Mühlenen I, Li Y. et al. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem 2007; 53 (09) 1609-1614
  • 10 Goldshtein H, Hausmann MJ, Douvdevani A. A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Ann Clin Biochem 2009; 46 (Pt 6): 488-494
  • 11 Agassi R, Czeiger D, Shaked G. et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am J Clin Pathol 2015; 143 (01) 18-24
  • 12 Avriel A, Paryente Wiessman M, Almog Y. et al. Admission cell free DNA levels predict 28-day mortality in patients with severe sepsis in intensive care. PLoS One 2014; 9 (06) e100514
  • 13 Localities in Israel.. 2008–2017. Central Bureau of Statistics Web site. Accessed February 06, 2019 at: https://www.cbs.gov.il/he/mediarelease/DocLib/2019/042/01_19_042b.pdf
  • 14 Rafaeli-Yehudai T, Imterat M, Douvdevani A. et al. Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation. PLoS One 2018; 13 (07) e0200360
  • 15 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114: 192-202
  • 16 Brouillette RT, Waxman DH. National Academy of Clinical Biochemistry. Evaluation of the newborn's blood gas status. Clin Chem 1997; 43 (01) 215-221
  • 17 Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am 1997; 11 (01) 135-176
  • 18 Nguyen DN, Stensballe A, Lai JC. et al. Elevated levels of circulating cell-free DNA and neutrophil proteins are associated with neonatal sepsis and necrotizing enterocolitis in immature mice, pigs and infants. Innate Immun 2017; 23 (06) 524-536
  • 19 Houben ML, Nikkels PG, van Bleek GM. et al. The association between intrauterine inflammation and spontaneous vaginal delivery at term: a cross-sectional study. PLoS One 2009; 4 (08) e6572